Key result
Growth hormone dysregulation is linked to atherogenic lipoprotein abnormalities and increased atherosclerosis risk.
Why the study?
The cholesterol-lowering effect of growth hormone administration and its impact on LDL kinetics have not been investigated in detail despite known associations with serum lipoprotein abnormalities.
Answers are grounded in this paper and cite their sources.
It has been known for more than 30 years that growth hormone has a lipolytic properties and growth hormone excess (acromegaly) and growth hormone deficiency have been reported to be associated with abnormalities in serum lipoprotein concentrations. Due to the lipolytic effect of growth hormone, its administration in man has been reported to increase plasma nonesterified fatty acid (NEFA) concentrations. Ketone body production increases during acute growth hormone excess as a result of increased NEFA concentrations; similarly, the increase in serum triglycerides may be explained by an increase in substrate (NEFA) supply to the liver for VLDL production. The effect may be enhanced by a simultaneous decrease of serum lipoprotein lipase activity. The cholesterol-lowering effect of growth hormone administration has not been investigated in detail, specifically, the effect of growth hormone on LDL kinetics is unknown. Growth hormone-excess and growth hormone deficiency have been reported to be associated with increased risk for atherosclerosis; an association with serum lipoprotein changes is likely but evidence for a causal link is yet lacking.
No takes yet. Share an insight, caveat, or question.
Ulrich Bernd Keller (2008) conducted a review in Growth hormone excess (acromegaly) and deficiency. Growth hormone was evaluated. Growth hormone administration increases plasma nonesterified fatty acids, while growth hormone excess or deficiency is associated with lipoprotein abnormalities and increased atherosclerosis risk.
Synapse has enriched 10 related papers. Consider them for comparative context: